Form 4: Baker Bros. Affiliates Report Acquisition of Kodiak Sciences Stock Options for Director Compensation

Baker Bros. Advisors and affiliated entities, including directors Felix and Julian Baker, reported the acquisition of 40,000 non-qualified stock options in Kodiak Sciences Inc. granted to Felix J. Baker as part of his director compensation.

Summary

• Reporting persons, including Baker Bros. Advisors LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, Felix J. Baker, and Julian C. Baker, filed a Form 4 with the SEC.
• The filing reports the acquisition of 40,000 non-qualified stock options in Kodiak Sciences Inc. (KOD).
• The options were granted to Felix J. Baker, a director of Kodiak Sciences Inc. and a managing member of Baker Bros. Advisors (GP) LLC, on June 30, 2025.
• The strike price for these options is $3.73 per share.
• The options vest on the earlier of June 30, 2026 (the first anniversary of the grant date) or one day prior to the date of the next annual meeting of stockholders, contingent on Felix J. Baker's continued service on the board.
• The options expire on June 29, 2035.
• The options are held indirectly for the benefit of 667, L.P. and Baker Brothers Life Sciences, L.P. (the 'Funds'), as per Baker Bros. Advisors' policy that directors do not directly retain compensation securities.
• Baker Bros. Advisors LP, as the investment adviser, maintains complete and unlimited discretion and authority over the investment and voting power of these securities held for the benefit of the Funds.

Sentiment

Score: 7

Explanation: The document reports a standard grant of stock options to a director, which is a routine compensation event. It indicates continued alignment of a significant institutional investor (Baker Bros.) with the company's long-term prospects, which is a positive signal, but does not contain new operational or financial news.

Positives

• A significant investment firm, Baker Bros. Advisors, and its principals, continue to hold director and 10% owner positions in Kodiak Sciences Inc., indicating continued strategic interest and alignment.
• The grant of long-term stock options to a director aligns his interests with long-term shareholder value, as the options vest over time and have a 10-year expiration, incentivizing sustained company performance.

Risks

• The value of the stock options is contingent on the future stock price of Kodiak Sciences Inc. exceeding the strike price of $3.73 per share.
• Vesting of the options is subject to Felix J. Baker's continued service on the board of directors, posing a risk if his service ceases before the vesting conditions are met.

Future Outlook

The grant of long-term stock options to a key director suggests an expectation of future value creation for Kodiak Sciences Inc., aligning management and significant shareholder interests with long-term performance.

Management Comments

• Felix J. Baker serves on the Board as a representative of 667, L.P. and Baker Brothers Life Sciences, L.P. and their affiliates and control persons.
• Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, L.P. and Baker Brothers Life Sciences, L.P.
• Baker Bros. Advisors LP serves as the investment adviser to the Funds and has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds.
• Pursuant to the policies of the Adviser, Felix J. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, specifically director compensation in the form of stock options. In the biotechnology and pharmaceutical industry, such equity grants are common mechanisms to incentivize directors and align their interests with the company's long-term success, particularly given the often long development cycles and high-risk, high-reward nature of drug development.

Comparison to Industry Standards

• The grant of stock options as director compensation is a standard practice across many industries, including biotechnology, to align director incentives with shareholder value.
• The strike price of $3.73 per share is the market price at the time of grant, which is typical for non-qualified stock options, ensuring that the options only gain value if the stock price appreciates.
• The 10-year expiration period (until June 29, 2035) is a common long-term incentive horizon for such equity grants in the biotech sector, reflecting the extended timelines for drug development and commercialization.

Corporate Governance

Related Party Transactions

• The grant of stock options to Felix J. Baker, a director of Kodiak Sciences Inc. and a managing member of Baker Bros. Advisors (GP) LLC, which is the general partner of Baker Bros. Advisors LP, the investment adviser to 667, L.P. and Baker Brothers Life Sciences, L.P.
• The indirect pecuniary interest of Julian C. Baker and Felix J. Baker in these options through their ownership interests in Baker Biotech Capital, L.P., Baker Brothers Life Sciences Capital, L.P., and the Funds.
• The arrangement where Felix J. Baker does not directly retain the compensation securities, but the affiliated Funds receive an indirect proportionate pecuniary interest, with Baker Bros. Advisors having voting and dispositive power over these securities.

Stakeholder Impact

• Shareholders: The grant of stock options to a director, particularly one representing a significant institutional investor, aligns the director's interests with long-term shareholder value creation. The options only become valuable if the stock price increases, incentivizing performance.
• Management/Directors: Felix J. Baker receives equity compensation for his board service, incentivizing his continued contribution to the company's strategic direction.
• Baker Bros. Advisors and Affiliates: The transaction increases their indirect beneficial ownership in Kodiak Sciences Inc., reinforcing their strategic position and influence as a major shareholder.

Next Steps

• Continued service of Felix J. Baker on the Kodiak Sciences Inc. board of directors for the options to vest.
• Future exercise of the stock options by the beneficial owners, contingent on the stock price exceeding the strike price.

Key Dates

Recommendation

Keywords

Kodiak Sciences Inc., KOD, SEC Form 4, Insider Transaction, Stock Options, Non-Qualified Stock Options, Director Compensation, Baker Bros. Advisors, Felix J. Baker, Julian C. Baker, Equity Incentive Plan, Biotechnology, Pharmaceuticals